| NCT06489457 | University Medical Centre Ljubljana | Type 2 Diabetes Mellitus|Obesity|Functional Hypogonadism | 2020-09-20 | PHASE3 |
| NCT05779644 | RenJi Hospital | Metformin|Obesity, Abdominal|Diabetes Mellitus, Type 2|Abdominal Fat|Non-Alcoholic Fatty Liver Disease|Metabolism Disorder, Glucose|Metabolism Disorder, Lipid | 2023-02-23 | NA |
| NCT06754163 | St Andrew´s Healthcare|Loughborough University | Obesity and Obesity-related Medical Conditions|Psychiatric Disorders | 2025-01-01 | PHASE4 |
| NCT06161844 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Type 2 Diabetes Mellitus | 2024-02-23 | PHASE3 |
| NCT07400107 | Novo Nordisk A+S | Obesity|Overweight|Diabetes Mellitus, Type 2 | 2026-05-20 | PHASE3 |
| NCT05822830 | Eli Lilly and Company | Obesity|Overweight | 2023-04-21 | PHASE3 |
| NCT07275697 | Emma Svennberg|Karolinska Institutet | Atrial Fibrillation (AF)|Obesity & Overweight | 2025-12-15 | PHASE4 |
| NCT06629688 | University Hospital Dubrava | Diabetes Mellitus Type 2|Iron Absorption | 2023-11-01 | NA |
| NCT03987074 | Gilead Sciences|Novo Nordisk A+S | Nonalcoholic Steatohepatitis | 2019-07-29 | PHASE2 |
| NCT04287179 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2020-03-09 | PHASE3 |
| NCT03811561 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2019-05-08 | PHASE3 |
| NCT06221969 | Novo Nordisk A+S | Type 2 Diabetes | 2024-01-16 | PHASE3 |
| NCT06289504 | Novo Nordisk A+S | Obesity | 2024-02-27 | PHASE1 |
| NCT04109508 | Novo Nordisk A+S | Healthy Volunteers|Type 2 Diabetes | 2019-10-02 | PHASE1 |
| NCT07163624 | The United Bio-Technology (Hengqin) Co., Ltd. | Type 2 Diabetes Mellitus (T2DM) | 2025-03-22 | PHASE2 |
| NCT04865744 | University of Tartu | Healthy | 2021-05-19 | PHASE4 |
| NCT04067999 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2019-08-05 | |
| NCT06975111 | University of Colorado, Denver | Menopause|Menopause Hot Flashes|Menopause Related Conditions|Cardiovascular | 2026-03-01 | PHASE2|PHASE3 |
| NCT06633783 | Hangzhou Jiuyuan Gene Engineering Co. Ltd., | Obesity | 2024-10-30 | PHASE3 |
| NCT05702931 | Rigshospitalet, Denmark|Aarhus University Hospital|Odense University Hospital | Hyperglycemia|Renal Transplant Complication Primary Non-Function|Diabetes | 2024-09-19 | PHASE4 |
| NCT03552757 | Novo Nordisk A+S | Obesity|Overweight | 2018-06-04 | PHASE3 |
| NCT05486065 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2022-08-08 | PHASE2 |
| NCT06934655 | Children´s Hospital Los Angeles | Pediatric Obesity|Metabolic and Bariatric Surgery|Semaglutide | 2026-06-01 | PHASE3 |
| NCT06256549 | Gan and Lee Pharmaceuticals, USA | Type 2 Diabetes | 2023-08-09 | PHASE2 |
| NCT05984238 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Endogenex | Diabetes Mellitus, Type 2 | 2023-08-03 | NA |
| NCT04777396 | Novo Nordisk A+S | Early Alzheimer´s Disease | 2021-05-18 | PHASE3 |
| NCT06764056 | Institut universitaire de cardiologie et de pneumologie de Québec, University Laval | Metabolic Associated Fatty Liver Disease|Metabolic Associated-dysfunction Steatohepatitis (MASH)|Obesity | 2025-01 | NA |
| NCT02161588 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2|Healthy | 2014-06 | PHASE1 |
| NCT03574597 | Novo Nordisk A+S | Overweight|Obesity | 2018-10-24 | PHASE3 |
| NCT06478550 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2024-06-26 | |
| NCT06468748 | United States Army Research Institute of Environmental Medicine | Obesity | 2024-08-01 | PHASE4 |
| NCT06691243 | University of Maryland, Baltimore|National Institutes of Health (NIH) | Cocaine Use Disorder|HIV | 2025-08-07 | PHASE2 |
| NCT04940078 | Novo Nordisk A+S | Obesity & Overweight | 2021-07-07 | PHASE1 |
| NCT03985384 | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Type 2 Diabetes|Coronary Artery Disease | 2019-04-30 | PHASE4 |
| NCT07272343 | Second Affiliated Hospital of Nanchang University | Type 2 Diabetes Mellitus (T2DM)|Semaglutide|Caloric Restriction | 2023-02-10 | PHASE4 |
| NCT01866748 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2|Healthy | 2013-05 | PHASE1 |
| NCT07295223 | Instituto Mexicano del Seguro Social|Universidad de Guanajuato | Acute Myocardial Infarction With ST Elevation | 2025-12-30 | PHASE3 |
| NCT06959784 | China-Japan Friendship Hospital | Diabetes Mellitus|Cardiovascular Diseases|Cerebrovascular Disease | 2024-01-01 | PHASE4 |
| NCT06541509 | University Medical Centre Ljubljana|Stanford University|Greenstone Biosciences | Heart Failure|Obesity | 2024-07-10 | PHASE1|PHASE2 |
| NCT07282769 | University of Chicago | Trichotillomania (Hair-Pulling Disorder)|Trichotillomania|Hair Pulling Disorder|Hair Pulling|Hair-Pulling Disorder | 2026-05 | PHASE2 |
| NCT04865770 | Novo Nordisk A+S | Diabetes Mellitus, Type 2|Chronic Kidney Disease | 2021-04-28 | PHASE3 |
| NCT06301191 | Attikon Hospital | Diabetes Type 2 | 2022-03-01 | |
| NCT05780905 | University of Washington|Novo Nordisk A+S | Diabetes Mellitus, Type 2|Stroke (CVA) or Transient Ischemic Attack | 2024-01-11 | PHASE4 |
| NCT06555146 | Bispebjerg Hospital | Diabetes Mellitus, Type 2|Kidney Disease, Chronic | 2024-08 | NA |
| NCT05071417 | Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León | Atheroscleroses, Coronary | 2021-11 | PHASE3 |
| NCT06852391 | McMaster University|Canadian Institutes of Health Research (CIHR)|Diabetes Canada | Obesity (Disorder) | 2025-06-18 | PHASE4 |
| NCT07317115 | GT Metabolic Solutions, Inc. | Obesity (Disorder)|Obesity & Overweight|Type 2 Diabetes (T2DM) | 2026-03 | NA |
| NCT01885208 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2013-12-02 | PHASE3 |
| NCT06283667 | Novo Nordisk A+S | Obesity | 2024-06-11 | |
| NCT07302802 | Prof. Dr. Martin Wabitsch|Novo Nordisk A+S | Monogenic Obesity | 2025-12-01 | |
| NCT07055607 | Novo Nordisk A+S | Obesity | 2025-11-21 | |
| NCT03466567 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2018-03-15 | PHASE1 |
| NCT04944992 | Merck Sharp & Dohme LLC | Nonalcoholic Fatty Liver Disease|Nonalcoholic Steatohepatitis | 2021-08-04 | PHASE2 |
| NCT06390501 | Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences | Obesity; Drug | 2024-04-01 | NA |
| NCT05035095 | Novo Nordisk A+S | Obesity|Overweight | 2021-09-13 | PHASE3 |
| NCT02906930 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2016-09-20 | PHASE3 |
| NCT06642584 | Novo Nordisk A+S | Healthy Volunteers Type 2 Diabetes | 2024-10-15 | PHASE1 |
| NCT07466017 | Cascade Pharmaceuticals, Inc | Metabolic Dysfunction-associated Steatohepatitis (MASH)|Obesity | 2026-04-02 | PHASE2 |
| NCT04513704 | Novo Nordisk A+S | Healthy Volunteers Type 2 Diabetes | 2020-08-28 | PHASE1 |
| NCT05813925 | Novo Nordisk A+S | Obesity or Overweight | 2023-04-03 | PHASE3 |
| NCT06388187 | Novo Nordisk A+S | Obesity | 2024-06-24 | PHASE3 |
| NCT05302596 | State University of New York at Buffalo|National Center for Advancing Translational Sciences (NCATS) | Obesity|Aging | 2022-09-01 | PHASE2 |
| NCT05132088 | Novo Nordisk A+S | Overweight and Obesity | 2021-11-16 | PHASE3 |
| NCT04878406 | Novo Nordisk A+S | Healthy Volunteers Type 2 Diabetes | 2021-05-18 | PHASE1 |
| NCT04560998 | Novo Nordisk A+S | Diabetes Mellitus, Type 2|Peripheral Arterial Disease | 2020-10-01 | PHASE3 |
| NCT05579249 | Novo Nordisk A+S | Obesity | 2023-01-19 | PHASE4 |
| NCT07135245 | Rune Skovgaard Rasmussen|Herlev Hospital | Alzheimer Disease (AD) | 2026-01-01 | PHASE2 |
| NCT07430332 | Children´s Hospital Medical Center, Cincinnati | Stage 1 Diabetes Mellitus, Type 1 | 2027-09-01 | PHASE2 |
| NCT04187300 | Novo Nordisk A+S | Overweight|Obesity | 2019-12-16 | PHASE1 |
| NCT04259801 | Novo Nordisk A+S | Healthy Volunteers|Overweight|Obesity|Diabetes Mellitus, Type 2 | 2020-02-17 | PHASE1 |
| NCT06619015 | Esbjerg Hospital - University Hospital of Southern Denmark | Obesity|Appetite Regulation|PreDiabetes | 2025-04-01 | PHASE2|PHASE3 |
| NCT05443568 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2023-03-09 | |
| NCT07043361 | Hillel Yaffe Medical Center | Metabolic Disease | 2023-12-18 | |
| NCT05016882 | Novo Nordisk A+S | Non-alcoholic Steatohepatitis | 2021-08-31 | PHASE2 |
| NCT05714683 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2025-12-31 | |
| NCT05813912 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2023-09-22 | PHASE3 |
| NCT06557811 | University of Sao Paulo General Hospital | Diabetic Patients|Acute Myocardial Infarction | 2024-09-01 | PHASE4 |
| NCT06699329 | Merck Sharp & Dohme LLC | Healthy | 2024-01-22 | PHASE1 |
| NCT05153564 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2021-12-13 | PHASE1 |
| NCT05442450 | Asian Institute of Gastroenterology, India | Obesity|Weight Loss | 2022-07-10 | PHASE4 |
| NCT02461589 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2015-09-21 | PHASE2 |
| NCT05829460 | Washington University School of Medicine|Novo Nordisk A+S | Endometrial Hyperplasia | 2025-03-12 | PHASE2 |
| NCT07271251 | Novo Nordisk A+S | Type 2 Diabetes | 2025-12-01 | PHASE3 |
| NCT07430059 | Vivani Medical, Inc|Avance Clinical Pty Ltd. | Obesity & Overweight | 2026-04 | PHASE1 |
| NCT05530577 | University of North Carolina, Chapel Hill|National Institute on Drug Abuse (NIDA) | Tobacco Use Disorder|Nicotine Addiction | 2022-10-07 | PHASE2 |
| NCT06097390 | Novo Nordisk A+S | Healthy Participants | 2023-09-28 | PHASE1 |
| NCT06571383 | Novo Nordisk A+S | Obesity | 2024-09-17 | PHASE4 |
| NCT07202247 | City of Hope Medical Center|National Cancer Institute (NCI) | Prostate Carcinoma|Recurrent Prostate Carcinoma | 2026-01-23 | PHASE2 |
| NCT05857085 | General and Teaching Hospital Celje | Endothelial Dysfunction|Diabetes Mellitus, Type 1|Biomarkers|Endothelial Progenitor Cells|SGLT 2 Inhibitors|Incretins|Glucose Excursions|FMD|FPF|Arterial Stiffness | 2021-12-15 | PHASE4 |
| NCT05305794 | Centre Hospitalier Universitaire Dijon | Double Diabetes | 2022-07-12 | PHASE3 |
| NCT07187856 | ProGen. Co., Ltd. | Type 2 Diabetes Mellitus (T2DM) | 2026-01 | PHASE2 |
| NCT06616961 | Popular Medical College Hospital|Pi Research and Development Center, Bangladesh|Incepta Pharmaceuticals Ltd | Obesity|Type 2 Diabetes Mellitus (T2DM) | 2024-11-01 | PHASE3 |
| NCT06083675 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2024-01-26 | PHASE3 |
| NCT06338553 | Vanderbilt University Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type 1 Diabetes | 2024-06-12 | EARLY_PHASE1 |
| NCT04228354 | Novo Nordisk A+S | Healthy Volunteers|Overweight|Obesity | 2020-01-29 | PHASE1 |
| NCT03899402 | State University of New York at Buffalo|University of Glasgow|Juvenile Diabetes Research Foundation | Type 1 Diabetes Mellitus | 2019-05-01 | PHASE2|PHASE3 |
| NCT06982859 | Eli Lilly and Company | Diabetes Mellitus|Insulin Sensitivity | 2025-06-02 | PHASE1 |
| NCT07218354 | VA Office of Research and Development | Alcohol Use Disorder | 2026-07-01 | PHASE3 |
| NCT03010475 | Novo Nordisk A+S | Diabetes|Healthy | 2017-01-05 | PHASE1 |
| NCT05249881 | Aga Khan University|Rehman Medical Institute - RMI | Diabetes Mellitus, Type 2|Weight Change, Body | 2022-03-10 | EARLY_PHASE1 |
| NCT04263415 | University Medical Centre Ljubljana | PCOS|Semaglutide|Taste, Altered|Tongue Tissue Transcriptome|Gastric Emptying|Central Neural Response | 2019-11-02 | PHASE4 |
| NCT04007107 | Novo Nordisk A+S | Healthy Volunteers Diabetes Mellitus, Type 2|Healthy Volunteers Overweight|Healthy Volunteers Obesity | 2019-06-27 | PHASE2 |
| NCT02231684 | Novo Nordisk A+S | Diabetes|Healthy | 2014-09 | PHASE1 |
| NCT03811574 | Novo Nordisk A+S | Overweight|Obesity | 2019-01-21 | PHASE3 |
| NCT05230589 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2022-04-25 | |
| NCT07059377 | Ottawa Heart Institute Research Corporation | Diabetes Mellitus, Type 2|Nicotine Addiction|Tobacco Dependence | 2025-09 | PHASE3 |
| NCT04061200 | Steno Diabetes Center Copenhagen|Novo Nordisk A+S | Type 2 Diabetes With Renal Manifestations | 2019-11-01 | PHASE4 |
| NCT07323134 | Beijing Chao Yang Hospital | Obesity | 2026-02-01 | |
| NCT04873050 | Woman´s|Novo Nordisk A+S | Pre Diabetes|Postpartum Disorder | 2022-01-13 | PHASE4 |
| NCT02607865 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2016-02-15 | PHASE3 |
| NCT06027567 | Rigmor H?jland Jensen|Rigshospitalet, Denmark|Odense University Hospital|University of Copenhagen | Idiopathic Intracranial Hypertension|Intracranial Pressure|Obesity|Pseudotumor Cerebri Syndrome|Papilledema|Weight Loss | 2022-09-02 | PHASE4 |
| NCT07511543 | Population Health Research Institute | Ischemic Stroke | 2026-06-30 | PHASE2 |
| NCT06762314 | Mostafa Bahaa|Meshal Saud Alotaibi, Senior Clinical Pharmacist, King Salman Speicialist Hospital-Hail, K.S.A.|Tanta University | Diabetes | 2025-01-20 | PHASE2 |
| NCT07227948 | The University of Texas Health Science Center, Houston|National Institute on Drug Abuse (NIDA) | Cocaine Use Disorder | 2026-01-15 | PHASE2 |
| NCT06745284 | Boehringer Ingelheim | Obesity | 2025-03-26 | PHASE1 |
| NCT06977438 | University of Minnesota|Patient-Centered Outcomes Research Institute|Novo Nordisk A+S | Obesity, Childhood | 2027-01-01 | PHASE4 |
| NCT06814938 | Mayo Clinic|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Phenomix Sciences | Obesity | 2025-02-21 | PHASE4 |
| NCT05193578 | Jan Frystyk|Region Zealand|Region of Southern Denmark|Steno Diabetes Center Sjaelland|Steno Diabetes Center Odense | Schizophrenia|Prediabetic State | 2022-01-01 | PHASE2 |
| NCT07251556 | Chinese University of Hong Kong | Psoriasis Arthritis | 2025-12-01 | PHASE4 |
| NCT06914141 | Brigham and Women´s Hospital | Diabetes Mellitus, Type 2|HFpEF - Heart Failure With Preserved Ejection Fraction | 2025-01-14 | |
| NCT05870462 | Canadian Medical and Surgical Knowledge Translation Research Group|Unity Health Toronto|Western University, Canada | Atherosclerosis|Cardiovascular Diseases|Diabetes Mellitus, Type 2|Obesity | 2023-04-29 | PHASE4 |
| NCT01272973 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2|Healthy | 2011-01 | PHASE1 |
| NCT02060266 | Novo Nordisk A+S | Diabetes|Healthy | 2014-02-04 | PHASE1 |
| NCT06989203 | Chinese Academy of Sciences | Obesity|Weight Loss|Protein Supplementation | 2025-06-10 | NA |
| NCT05195944 | University Health Network, Toronto|Novo Nordisk A+S | Liver Transplant; Complications|Diabetes Mellitus|NASH - Nonalcoholic Steatohepatitis|NAFLD | 2022-10-26 | PHASE4 |
| NCT03724981 | Eli Lilly and Company | Diabetes Mellitus, Type 2 | 2018-10-18 | PHASE4 |
| NCT05646199 | University of Hull | Polycystic Ovary Syndrome | 2025-03-01 | PHASE2|PHASE3 |
| NCT05533632 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2022-04-25 | PHASE4 |
| NCT06287307 | Zuyderland Medisch Centrum|Nederlandse Obesitas Kliniek | Obesity|Obesity, Morbid|Weight Gain | 2024-05 | PHASE4 |
| NCT06299098 | Regeneron Pharmaceuticals | Obesity | 2024-03-13 | PHASE2 |
| NCT04016974 | Novo Nordisk A+S | Healthy Volunteers|Diabetes Mellitus, Type 2 | 2019-10-08 | PHASE1 |
| NCT06575738 | University of Colorado, Denver|National Heart, Lung, and Blood Institute (NHLBI) | Obesity|Adolescent Obesity|Body-Weight Trajectory|Weight Loss Trajectory|Bariatric Surgery|Anti-obesity Agents | 2024-10-11 | PHASE1 |
| NCT06282458 | Veru Inc. | Muscle Loss|Obesity | 2024-04-29 | PHASE2 |
| NCT05669755 | Novo Nordisk A+S | Cardiovascular Disease | 2023-03-01 | PHASE3 |
| NCT04216589 | National Institute of Allergy and Infectious Diseases (NIAID)|The University of Texas Health Science Center, Houston | HIV Infections|Non-Alcoholic Fatty Liver Disease | 2021-02-19 | PHASE2 |
| NCT02243098 | Novo Nordisk A+S | Diabetes|Healthy | 2014-09-16 | PHASE1 |
| NCT07391267 | Institute of Liver and Biliary Sciences, India | Chronic Kidney Diseases|MAFLD | 2026-02-01 | NA |
| NCT03457012 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2018-03-29 | |
| NCT02305381 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2014-12-01 | PHASE3 |
| NCT05822609 | University of Washington|Juvenile Diabetes Research Foundation|University of Colorado, Denver|Providence Healthcare|University of Toronto | Diabetic Kidney Disease|Type 1 Diabetes | 2024-04-05 | PHASE2 |
| NCT05766709 | Novo Nordisk A+S | Non-alcoholic Steatohepatitis | 2023-03-02 | PHASE1 |
| NCT06409130 | Novo Nordisk A+S | Alcohol-related Liver Disease | 2024-05-20 | PHASE2 |
| NCT05303857 | University of Erlangen-Nürnberg Medical School | Diabetes Mellitus, Type 2 | 2022-03-03 | PHASE4 |
| NCT06499857 | University of Chicago | Overweight or Obesity|Atrial Fibrillation | 2025-04-14 | PHASE3 |
| NCT04979130 | University of Colorado, Denver|Novo Nordisk A+S | Type 2 Diabetes|Chronic Inflammation|Intestinal Permeability | 2022-01-01 | PHASE4 |
| NCT04097600 | Novo Nordisk A+S | Healthy Volunteers|Type 2 Diabetes | 2019-09-30 | PHASE1 |
| NCT03987451 | Novo Nordisk A+S | Non-alcoholic Steatohepatitis | 2019-06-18 | PHASE2 |
| NCT07314684 | Federico II University | T2DM (Type 2 Diabetes Mellitus) | 2025-09-08 | PHASE4 |
| NCT04537624 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2020-08-24 | |
| NCT07294950 | Mount Sinai Hospital, Canada|Heart and Stroke Foundation of Canada | Obesity (Disorder)|Weight Change|Blood Pressure Monitoring|Appetite Regulation | 2026-02-01 | PHASE3 |
| NCT07030621 | RenJi Hospital | Acute Ischemic Stroke | 2025-07-01 | PHASE3 |
| NCT06361823 | Capital Medical University | Idiopathic Intracranial Hypertension | 2024-05-01 | PHASE3 |
| NCT07513168 | Asian Institute Of Medical Sciences | Obesity|Weight Reduction|Cardiometabolic Risk Factors | 2025-08-01 | PHASE4 |
| NCT02064348 | Novo Nordisk A+S | Diabetes|Healthy | 2014-02-26 | PHASE1 |
| NCT06363487 | University of Oxford|National Institute for Health Research, United Kingdom | Cognitive Change | 2024-06-06 | NA |
| NCT06989177 | Chinese Academy of Sciences | Obesity|Homeostasis|Weight Loss|Probiotic Intervention | 2025-06-10 | NA |
| NCT04971785 | Gilead Sciences|Novo Nordisk A+S | Nonalcoholic Steatohepatitis | 2021-08-09 | PHASE2 |
| NCT05419726 | University of California, Los Angeles | Obesity | 2023-02-01 | |
| NCT05577728 | Brigham and Women´s Hospital | Diabetes Mellitus, Type 2 | 2021-07-01 | |
| NCT05816057 | Hangzhou Jiuyuan Gene Engineering Co. Ltd., | Diabetes Mellitus, Type 2 | 2022-07-25 | PHASE3 |
| NCT02022254 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2|Healthy | 2013-12-17 | PHASE1 |
| NCT07200622 | Imperial College London | Alzheimer Disease | 2025-09-25 | PHASE2 |
| NCT05514535 | Novo Nordisk A+S | Diabetes Mellitus, Type 2|Obesity | 2022-08-29 | PHASE3 |
| NCT03876015 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2019-05-01 | |
| NCT07285902 | Fujian Shengdi Pharmaceutical Co., Ltd. | Obesity | 2025-12-25 | PHASE3 |
| NCT04873245 | University of Minnesota | Obesity, Childhood | 2022-03-15 | PHASE2 |
| NCT07297589 | Instituto Mexicano del Seguro Social | STEMI - ST Elevation Myocardial Infarction|Epicardial Fat | 2025-12-30 | PHASE3 |
| NCT06706284 | Marzieh Salehi|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Spinal Cord Injuries|Type 2 Diabetes | 2025-04-11 | PHASE4 |
| NCT05340868 | Medical University of Bialystok | PreDiabetes|Prediabetic State|Obesity | 2022-09-01 | NA |
| NCT06041217 | Novo Nordisk A+S | Overweight|Obesity | 2023-09-15 | PHASE3 |
| NCT06260722 | Eli Lilly and Company | Diabetes Mellitus, Type 2 | 2024-02-21 | PHASE3 |
| NCT06884293 | Innovent Biologics (Suzhou) Co. Ltd. | Overweight|Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) | 2025-05-09 | PHASE3 |
| NCT03061214 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2017-08-28 | PHASE3 |
| NCT07101939 | Actimed Therapeutics Ltd|SCIRENT Clinical Research and Science d.o.o. | Obesity|Muscle Loss | 2025-06-23 | PHASE2 |
| NCT05689372 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2026-02-02 | |
| NCT05119179 | The University of Texas Health Science Center, Houston|Vanderbilt University Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | PreDiabetes | 2021-11-22 | PHASE4 |
| NCT06803888 | Ali Aminian|Ethicon, Inc. | Obesity and Obesity-related Medical Conditions | 2025-01-29 | PHASE4 |
| NCT02453711 | Novo Nordisk A+S | Metabolism and Nutrition Disorder|Obesity | 2015-10-01 | PHASE2 |
| NCT04012255 | Novo Nordisk A+S | Overweight|Obesity | 2019-07-15 | PHASE1 |
| NCT04998136 | Novo Nordisk A+S | Obesity | 2022-08-15 | PHASE3 |
| NCT05616052 | Huashan Hospital | Weight Change, Body | 2022-12-01 | PHASE4 |
| NCT07424430 | LMC Diabetes & Endocrinology Ltd. | Diabetes (DM)|Type 2 Diabetes|Obesity (Disorder) | 2026-03 | |
| NCT02877355 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2016-08-22 | PHASE1 |
| NCT06659718 | Brigham and Women´s Hospital | Diabetes Mellitus, Type 2 | 2024-10-24 | |
| NCT05478252 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2022-08-03 | PHASE3 |
| NCT06909006 | Nordsjaellands Hospital|Steno Diabetes Center Copenhagen|Steno Diabetes Center Odense|Zealand University Hospital|Aarhus University Hospital | Obesity in Diabetes|Obesity+Therapy|Type 1 Diabetes Mellitus (T1DM)|Insulin Sensitivity+Resistance|Semaglutide|Lipidomics|Metabolomics|Weight Loss|Glycemic Control for Diabetes Mellitus | 2025-10 | PHASE3 |
| NCT02648204 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2016-01-06 | PHASE3 |
| NCT07547878 | Baylor Research Institute | Chronic Kidney Disease|Type 2 Diabetes | 2026-04-30 | PHASE4 |
| NCT04102189 | Novo Nordisk A+S | Overweight|Obesity | 2019-10-07 | PHASE3 |
| NCT01720446 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2013-02-21 | PHASE3 |
| NCT05435677 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2022-06-22 | PHASE1 |
| NCT01324505 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2011-03 | PHASE1 |
| NCT05768945 | Brigham and Women´s Hospital|National Institute on Aging (NIA)|Rutgers University|Johns Hopkins University | Diabetes | 2022-11-30 | |
| NCT04817644 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2021-09-10 | PHASE1 |
| NCT04822181 | Novo Nordisk A+S | Non-alcoholic Steatohepatitis | 2021-04-01 | PHASE3 |
| NCT05468632 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2022-07-05 | |
| NCT04969939 | Novo Nordisk A+S | Obesity | 2021-07-15 | PHASE2 |
| NCT04707469 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2021-01-15 | PHASE3 |
| NCT05897372 | Iain Bressendorff | Diabetic Kidney Disease | 2023-08-01 | PHASE2 |
| NCT04143945 | Novo Nordisk A+S | Healthy Volunteers Diabetes Mellitus, Type 2|Healthy Volunteers Overweight|Healthy Volunteers Obesity | 2019-10-28 | PHASE2 |
| NCT04854083 | Kirsi Pietil?inen|University of Helsinki|Turku University Hospital | Type2 Diabetes | 2022-02-17 | PHASE4 |
| NCT05892432 | University of Colorado, Denver|National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcohol Use Disorder | 2024-01-11 | PHASE2 |
| NCT05429593 | Novo Nordisk A+S | Healthy Volunteers | 2022-06-22 | PHASE1 |
| NCT06608433 | University Hospital, Basel, Switzerland | Healthy Volunteer Study|HPA|Cortisol Deficiency|Adrenal Insufficiency | 2025-01-16 | NA |
| NCT06825793 | Beijing Chao Yang Hospital | Obesity | 2025-02-20 | NA |
| NCT03191396 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2017-06-27 | PHASE3 |
| NCT04383197 | University of Copenhagen | Type 2 Diabetes | 2019-12-10 | NA |
| NCT05333003 | Centre for Addiction and Mental Health | Schizophrenia Spectrum Disorders | 2022-05-25 | NA |
| NCT03693430 | Novo Nordisk A+S | Overweight|Obesity | 2018-10-05 | PHASE3 |
| NCT03548987 | Novo Nordisk A+S | Metabolism and Nutrition Disorder|Obesity | 2018-06-04 | PHASE3 |
| NCT02016911 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2|Healthy | 2013-12-12 | PHASE1 |
| NCT04175665 | LMC Diabetes & Endocrinology Ltd. | Type 2 Diabetes | 2020-01-06 | |
| NCT04878393 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2021-04-30 | |
| NCT06182618 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Metabolic Syndrome | 2023-06-01 | |
| NCT04094415 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2019-10-28 | |
| NCT07253285 | Novo Nordisk A+S | Overweight|Obesity | 2026-01-08 | PHASE3 |
| NCT05689099 | Novo Nordisk A+S | Diabetes Mellitus, Type 2|Healthy Participants | 2023-01-17 | PHASE1 |
| NCT07011667 | Novo Nordisk A+S | Obesity | 2025-06-03 | PHASE3 |
| NCT07554417 | William Marsh Rice University|The Methodist Hospital Research Institute | GLP - 1|Obesity & Overweight|Muscle Loss|Exercise Intervention|Dietary Assessment | 2026-04-06 | PHASE4 |
| NCT05751226 | Boehringer Ingelheim | Healthy|Obesity | 2023-04-11 | PHASE1 |
| NCT04189848 | Novo Nordisk A+S | Healthy Volunteers|Diabetes Mellitus, Type 2|Overweight|Obesity | 2019-12-03 | PHASE4 |
| NCT07505303 | Eccogene | Adult Obesity|Weight Management | 2026-03-13 | PHASE2 |
| NCT07254572 | National Institute of Cardiology, Warsaw, Poland|Medical Research Agency, Poland | Coronary Artery Disease|PreDiabetes | 2025-07-10 | PHASE4 |
| NCT05671653 | Pfizer | Obesity | 2023-01-19 | PHASE1 |
| NCT05147896 | University Medical Centre Ljubljana|University of Palermo | Diabetes Mellitus, Type 2|Atherosclerosis | 2022-05-01 | NA |
| NCT05316662 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2022-04-06 | |
| NCT05996874 | Novo Nordisk A+S | Healthy Participants | 2023-08-12 | PHASE1 |
| NCT07136714 | Nordsjaellands Hospital | Major Depressive Disorder | 2025-09-11 | PHASE4 |
| NCT05071898 | University of Maryland, Baltimore | Obesity|Diabetes Type 2 | 2022-04-11 | PHASE1 |
| NCT06410352 | University Medical Center, Kazakhstan|Nazarbayev University School of Medicine|Nazarbayev University|Astana Medical University|Public Association "Eurasian Society of Personalized Medicine"|Ministry of Science and Higher Education of the Republic of Kazakhstan | Metabolic Syndrome | 2024-03-01 | PHASE4 |
| NCT06914102 | Brigham and Women´s Hospital | Diabetes Mellitus, Type 2|HFpEF - Heart Failure With Preserved Ejection Fraction | 2025-01-14 | |
| NCT05209165 | San Francisco Veterans Affairs Medical Center | Atrial Fibrillation|Obesity|Overweight | 2023-05 | PHASE4 |
| NCT02079870 | Novo Nordisk A+S | Diabetes|Metabolism and Nutrition Disorder|Obesity | 2014-03-06 | PHASE1 |
| NCT06986993 | University of Oklahoma | Tobacco Use | 2024-07-01 | PHASE4 |
| NCT06649344 | Fujian Shengdi Pharmaceutical Co., Ltd. | Type 2 Diabetes | 2024-10-31 | PHASE3 |
| NCT05726227 | Novo Nordisk A+S | Obesity | 2023-07-07 | PHASE3 |
| NCT04074161 | Novo Nordisk A+S | Overweight|Obesity | 2019-09-11 | PHASE3 |
| NCT07096063 | Brigham and Women´s Hospital | Type 2 Diabetes|Overweight|Cardiovascular (CV) Risk | 2024-10-01 | |
| NCT04777409 | Novo Nordisk A+S | Early Alzheimer?s Disease | 2021-05-18 | PHASE3 |
| NCT05574439 | Signe Torekov|University of Leeds|Karolinska Institutet|Holbaek Sygehus|Rigshospitalet, Denmark | Obesity, Adolescent | 2022-06-01 | PHASE4 |
| NCT03611322 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2018-08-08 | PHASE1 |
| NCT07361874 | University of Texas Southwestern Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Mild Autonomous Cortisol Secretion (MACS)|Autonomous Cortisol Secretion (ACS)|Subclinical Cushing´s|Mild Autonomous Cortisol Excess | 2026-03-05 | NA |
| NCT05502562 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2023-02-24 | |
| NCT07213466 | Mayo Clinic|University of Toronto | Bipolar I Disorder|Bipolar II Disorder|Schizo Affective Disorder|Obesity|Weight Loss|GLP - 1 | 2026-01-19 | PHASE4 |
| NCT06269120 | Novo Nordisk A+S | Type 2 Diabetes | 2024-09-30 | |
| NCT06339086 | Chengdu Brilliant Pharmaceutical Co., Ltd. | Type 2 Diabetes Mellitus | 2024-04 | PHASE3 |
| NCT07415954 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2026-04-17 | PHASE2 |
| NCT04889183 | University Medical Center Groningen|Novo Nordisk A+S | Obesity|Albuminuria | 2022-03-14 | PHASE3 |
| NCT05702905 | Peking University First Hospital | PCOS (Polycystic Ovary Syndrome)|Semaglutide | 2023-05-09 | PHASE4 |
| NCT07179120 | First Affiliated Hospital of Wenzhou Medical University | Obesity-related Male Infertility | 2026-05-01 | PHASE2 |
| NCT06913023 | University Health Network, Toronto | Kidney Transplant Recipient | 2026-01-05 | PHASE2|PHASE3 |
| NCT03600480 | Novo Nordisk A+S | Obesity|Overweight | 2018-07-25 | PHASE1 |
| NCT03548935 | Novo Nordisk A+S | Metabolism and Nutrition Disorder|Overweight or Obesity | 2018-06-04 | PHASE3 |
| NCT05073835 | University College, London | Obesity|Diabetes|Metabolic Syndrome | 2022-11-01 | PHASE3 |
| NCT02070510 | Novo Nordisk A+S | Diabetes|Healthy | 2014-02-27 | PHASE1 |
| NCT06954090 | Steno Diabetes Center Copenhagen|Mosaiques Diagnostics GmbH | Type 2 DM|Type 2 DM +Diabetic Nephropathy|Albuminuria | 2025-11-20 | PHASE4 |
| NCT02014259 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2|Healthy | 2013-12-11 | PHASE1 |
| NCT02128932 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2014-08-04 | PHASE3 |
| NCT04017832 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2019-07-29 | PHASE3 |
| NCT06546384 | Insel Gruppe AG, University Hospital Bern | Adiposity|Fatty Liver|Alcohol Use Disorder | 2026-05-01 | NA |
| NCT06184633 | Rijnstate Hospital | Atrial Fibrillation|Obesity|Weight Loss | 2024-07-21 | PHASE4 |
| NCT02054897 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2014-02-03 | PHASE3 |
| NCT06323174 | Novo Nordisk A+S | Type 2 Diabetes | 2024-03-19 | PHASE3 |
| NCT04032197 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2019-08-12 | PHASE1 |
| NCT05597202 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Dutch Heart Foundation | Type 2 Diabetes | 2023-01-01 | PHASE4 |
| NCT03919929 | University of Colorado, Denver|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | PCOS|Adolescent Obesity|NAFLD | 2019-05-03 | PHASE2|PHASE3 |
| NCT06604624 | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Weight Management | 2024-09-20 | PHASE3 |
| NCT07570810 | Shanghai Jiao Tong University School of Medicine | Type 2 Diabetes|Obesity|Non-alcoholic Fatty Liver Disease | 2026-06-01 | NA |
| NCT05046873 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2021-09-06 | PHASE1 |
| NCT07483801 | Cambridge University Hospitals NHS Foundation Trust | Cardiovascular Diseases | 2026-03 | PHASE4 |
| NCT06896981 | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Polycystic Ovary Syndrome (PCOS) Women|Obesity | 2025-02-01 | PHASE2|PHASE3 |
| NCT06792422 | Glostrup University Hospital, Copenhagen | Primary Open Angle Glaucoma (POAG)|Open-Angle Glaucoma|Glaucoma | 2025-01 | PHASE4 |
| NCT02863419 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2016-08-10 | PHASE3 |
| NCT03884075 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Cancer Institute (NCI) | Non-Alcoholic Steatohepatitis|Non-Alcoholic Fatty Liver Disease | 2019-07-24 | PHASE2 |
| NCT06648031 | Lexaria Bioscience Corp. | Type2diabetes | 2024-12-04 | PHASE1 |
| NCT07509112 | Kirby Institute | Methamphetamine Use Disorder | 2026-05 | PHASE2 |
| NCT07374328 | Second Affiliated Hospital of Guangzhou Medical University | Type 2 Diabetes | 2025-06-01 | PHASE1|PHASE2 |
| NCT06005012 | University of California, San Diego | Fibrosis, Liver|Type 2 Diabetes Mellitus in Obese|Non-Alcoholic Fatty Liver Disease | 2023-07-25 | PHASE2 |
| NCT07325500 | The University of Texas Health Science Center, Houston|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Colorado Denver - Anschutz Medical Campus (UCD-AMC)|Massachusetts General Hospital (MGH) | Weight Gain | 2026-02-12 | PHASE2 |
| NCT05670379 | Vivani Medical, Inc|Avance Clinical Pty Ltd. | Overweight and Obesity|Type2diabetes | 2024-12-20 | PHASE1 |
| NCT04447859 | Tel-Aviv Sourasky Medical Center | Diabetes type2 | 2020-02-23 | PHASE3 |
| NCT05371496 | Mayo Clinic|United States Department of Defense | Cardiomyopathy|Heart Failure With Preserved Ejection Fraction (HFpEF)|Obesity | 2022-09-06 | PHASE2 |
| NCT02249910 | Novo Nordisk A+S | Diabetes|Healthy | 2014-09-18 | PHASE1 |
| NCT07073417 | Hangzhou Sciwind Biosciences Co., Ltd. | Obesity|Weight Management | 2025-07-28 | PHASE2 |
| NCT03789578 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2019-01-17 | PHASE1 |
| NCT07195994 | QuickSilver Scientific|KGK Science Inc. | Prediabetes + Type 2 Diabetes | 2026-02-05 | NA |
| NCT05173714 | Srinvasan Beddhu|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Stanford University | Chronic Kidney Diseases|Obesity | 2021-12-01 | PHASE2 |
| NCT07280221 | Novo Nordisk A+S | Obesity | 2025-11-10 | |
| NCT06351748 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2024-01-02 | |
| NCT03598621 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2018-07-23 | PHASE1 |
| NCT05819138 | University of Colorado, Denver|National Heart, Lung, and Blood Institute (NHLBI) | Diabetes Mellitus, Type 1 | 2023-06-21 | PHASE3 |
| NCT06072963 | Rutgers, The State University of New Jersey|Alzheimer´s Association | Alzheimer Disease|Mild Cognitive Impairment|Metabolic Syndrome | 2024-01-30 | PHASE2 |
| NCT03292315 | James J. Peters Veterans Affairs Medical Center|Kessler Institute for Rehabilitation | Spinal Cord Injuries|Insulin Resistance|Pre Diabetes|Obesity | 2018-10-16 | PHASE4 |
| NCT06579105 | AstraZeneca | Diabetes Mellitus, Type 2 | 2024-10-08 | PHASE2 |
| NCT05586802 | Georgios Papadakis | Klinefelter Syndrome | 2023-03-21 | PHASE3 |
| NCT07139548 | Guangdong Raynovent Biotech Co., Ltd | T2DM | 2025-08-31 | PHASE3 |
| NCT04261933 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2020-02-13 | |
| NCT06851962 | Fundación para la Investigación del Hospital Clínico de Valencia|Instituto de Salud Carlos III|European Union | Diabetes Mellitus Type 2 | 2025-05-26 | PHASE4 |
| NCT03689374 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2018-10-01 | PHASE3 |
| NCT06937060 | The University of Hong Kong | Psoriasis (PsO)|Obesity and Overweight | 2025-03-20 | PHASE3 |
| NCT06974825 | BrightGene Bio-Medical Technology Co., Ltd. | Type 2 Diabetes | 2023-08-30 | PHASE2 |
| NCT04469855 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2020-07-27 | |
| NCT07010432 | Novo Nordisk A+S | Obesity | 2025-06-12 | PHASE1 |
| NCT05441267 | University of Oxford|Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2023-03-13 | PHASE4 |
| NCT06082063 | Steno Diabetes Center Copenhagen|Aarhus University Hospital|Steno Diabetes Center Nordjylland|Steno Diabetes Center Odense|Slagelse Hospital|Nyk?bing Falster County Hospital|Zealand University Hospital|Hillerod Hospital, Denmark|Rigshospitalet, Denmark|Hvidovre University Hospital|Regionshospitalet Viborg, Skive|Randers Regional Hospital|Herning Hospital|Esbjerg Hospital - University Hospital of Southern Denmark|Regionshospitalet Silkeborg|Bispebjerg Hospital|Regionshospitalet Horsens | Cardiovascular Diseases|Heart Failure|Type 1 Diabetes|Kidney Failure | 2024-07-01 | PHASE3 |
| NCT06207877 | Novo Nordisk A+S | Obesity | 2024-02-23 | PHASE1 |
| NCT01766245 | Novo Nordisk A+S | Diabetes|Healthy | 2012-12 | PHASE1 |
| NCT07112872 | Hoffmann-La Roche | Type 2 Diabetes Mellitus | 2025-08-19 | PHASE2 |
| NCT07319975 | Istanbul Galata University|Biruni University|Istanbul University | Obesity | 2025-12-29 | NA |
| NCT07021937 | University of Colorado, Denver|University of Minnesota|The Metis Foundation | Obesity+Therapy | 2026-05-01 | PHASE3 |
| NCT01619345 | Novo Nordisk A+S | Diabetes|Healthy | 2012-06 | PHASE1 |
| NCT07065383 | University of Aberdeen|NHS Grampian | Diabetes Mellitus Type 2 | 2025-08-01 | NA |
| NCT04916470 | Novo Nordisk A+S | Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2 | 2021-06-15 | PHASE3 |
| NCT07087795 | Novo Nordisk A+S | Diabetes Mellitus, Type 1 | 2025-07-01 | PHASE1 |
| NCT06396416 | Western University, Canada|London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph´s|Queen Elizabeth II Health Sciences Centre|Unity Health Toronto | Obesity|Chronic Kidney Disease | 2024-09-26 | PHASE4 |
| NCT04885634 | Axel Brandes|Herlev and Gentofte Hospital|Hillerod Hospital, Denmark|Svendborg Hospital|Esbjerg Hospital - University Hospital of Southern Denmark | Atrial Fibrillation|Overweight and Obesity | 2022-10 | PHASE3 |
| NCT07018544 | Novo Nordisk A+S | Obesity and Overweight | 2024-11-19 | |
| NCT07281196 | Shanghai Fengxian District Central Hospital | Sleep Apnea Syndrome (OSAS) | 2025-01-01 | |
| NCT03707990 | Novo Nordisk A+S | Obesity and Overweight | 2018-10-15 | PHASE1 |
| NCT07225816 | Novo Nordisk A+S | Obesity | 2025-11-07 | PHASE1 |
| NCT04559815 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2020-10-21 | |
| NCT04515849 | AstraZeneca | Type 2 Diabetes Mellitus|Chronic Kidney Diseases | 2020-08-31 | PHASE2 |
| NCT07057310 | Mayo Clinic | Obesity|Menopause | 2025-05-01 | PHASE4 |
| NCT06403761 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2024-05-06 | PHASE1 |
| NCT07485062 | Western University, Canada | Type 2 Diabetes|Cognitive Decline in Older Adults | 2026-05-01 | PHASE4 |
| NCT04639414 | German Diabetes Center|Boehringer Ingelheim|German Center for Diabetes Research|Federal Ministry of Health, Germany|Ministry of Innovation, Science and Research in North Rhine-Westphalia|Novo Nordisk A+S | Type 2 Diabetes|Non-alcoholic Steatohepatitis (NASH)|Non-alcoholic Fatty Liver Disease (NAFLD) | 2021-03-26 | PHASE4 |
| NCT05920889 | Chinese University of Hong Kong|Linyi People´s Hospital | Stroke|Stroke, Acute|Stroke, Ischemic|Brain Diseases | 2023-08-01 | PHASE2 |
| NCT02692716 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2017-01-17 | PHASE3 |
| NCT06243536 | University Hospital Sestre Milosrdnice|University of Zagreb | Type 2 Diabetes|Overweight|Disordered Eating Behaviors | 2024-02-01 | PHASE4 |
| NCT07523633 | Anders Fink-Jensen, MD, DMSci|Neurobiology Research Unit, Rigshospitalet | Cannabis Use Disorder|Cannabis Use Disorders|Cannabis Abuse|Cannabis Dependence|Cannabis Addiction | 2026-04-30 | PHASE2 |
| NCT06836284 | Karolinska Institutet|Evira AB | Childhood Obesity|Treatment Adherence | 2026-02-13 | NA |
| NCT05259033 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2022-04-11 | PHASE3 |
| NCT05891587 | Oklahoma State University Center for Health Sciences|National Institute of Drug Abuse | Alcohol Use Disorder | 2023-07-07 | PHASE2 |
| NCT07242534 | Fundacion Dexeus | Infertility|Obesity | 2026-01-19 | PHASE4 |
| NCT05786521 | The University of Texas Health Science Center at San Antonio|National Institute on Aging (NIA) | Aging|Diabetes Mellitus, Type 2|PreDiabetes|Overweight and Obesity | 2023-04-01 | PHASE4 |
| NCT05548647 | University of Pennsylvania|Novo Nordisk A+S | Obesity | 2022-07-26 | PHASE4 |
| NCT07284979 | Kailera | Obesity | 2025-12-30 | PHASE3 |
| NCT05254314 | Vanderbilt University Medical Center|National Institute of Allergy and Infectious Diseases (NIAID) | Asthma | 2022-10-11 | PHASE2 |
| NCT05819853 | University of Colorado, Denver|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries|Obese | 2023-11-03 | PHASE3 |
| NCT04601753 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2020-11-12 | |
| NCT06131437 | Novo Nordisk A+S | Obesity | 2023-11-27 | PHASE3 |
| NCT02207374 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2014-08-04 | PHASE3 |
| NCT05895643 | Psychiatric Centre Rigshospitalet|Neurobiology Research Unit | Alcohol Abuse|Alcohol Addiction|Alcohol Dependence|Alcohol Use Disorder | 2023-06-13 | PHASE2 |
| NCT02920385 | Novo Nordisk A+S | Diabetes|Healthy | 2016-10-10 | PHASE1 |
| NCT06577090 | Skye Bioscience, Inc. | Obesity | 2024-08-22 | PHASE2 |
| NCT07165158 | The First Affiliated Hospital of Xiamen University|Peking University First Hospital|Shanghai Punan Hospital of Pudong New District|Shanghai 6th People´s Hospital|Jinzhou Medical University | Osteoporosis|Osteoporosis Fracture|T2DM | 2025-09-15 | PHASE4 |
| NCT06411210 | Yale University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Novo Nordisk A+S | Diabetes type1|Obesity | 2024-07-16 | PHASE2 |
| NCT07457424 | University College Dublin|University of Zurich | Metabolic Disease|Obesity & Overweight | 2022-02-17 | |
| NCT05891496 | Novo Nordisk A+S | Alzheimers Disease | 2023-06-20 | PHASE3 |
| NCT06065540 | Novo Nordisk A+S | Type 2 Diabetes Mellitus | 2023-09-27 | PHASE3 |
| NCT04538352 | The Cleveland Clinic|Novo Nordisk A+S | Type 2 Diabetes | 2021-01-18 | PHASE4 |
| NCT03638778 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2018-08-17 | PHASE1 |
| NCT06801015 | Mayo Clinic | Obesity | 2025-10-01 | PHASE4 |
| NCT07204249 | San Francisco Department of Public Health | Methamphetamine-dependence | 2026-01-15 | PHASE2 |
| NCT05443191 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2022-10-20 | |
| NCT06894784 | McGill University Health Centre+Research Institute of the McGill University Health Centre|Diabetes Canada | Diabetes Type 1 | 2025-04 | PHASE3 |
| NCT05996848 | Novo Nordisk A+S | Obesity or Overweight | 2023-08-15 | PHASE3 |
| NCT05950516 | Qilu Pharmaceutical Co., Ltd. | Type 2 Diabetes | 2023-07-10 | PHASE3 |
| NCT07017270 | Unity Health Toronto | Kidney Disease, Chronic|Diabetes|Dialysis|End Stage Kidney Disease (ESRD) | 2025-07 | PHASE4 |
| NCT07064486 | BrightGene Bio-Medical Technology Co., Ltd. | Type 2 Diabetes (T2DM) | 2025-07-04 | PHASE3 |
| NCT04779697 | Yale University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Obesity | 2021-02-01 | PHASE1 |
| NCT04238962 | Novo Nordisk A+S | Overweight|Obesity | 2020-02-03 | PHASE1 |
| NCT01930188 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2013-12-02 | PHASE3 |
| NCT04741074 | Geisinger Clinic | CKD|Diabetic Kidney Disease|Type 2 Diabetes Mellitus in Obese|Obesity|Severe Obesity | 2021-07-23 | PHASE3 |
| NCT06908694 | Hamilton Health Sciences Corporation|McMaster University | Prostate Cancer | 2025-07-02 | PHASE4 |
| NCT07223983 | Yale University | Alcohol Use Disorder|Weight Loss|Bariatric Surgery Patients | 2026-03 | PHASE1 |
| NCT06780449 | Novo Nordisk A+S | Obesity | 2025-02-10 | PHASE3 |
| NCT06149260 | Second Xiangya Hospital of Central South University | Scleroderma, Systemic|Fibrosis|Semaglutide | 2024-02-29 | PHASE1 |
| NCT06267092 | Novo Nordisk A+S | Overweight|Obesity | 2024-02-15 | PHASE1 |
| NCT07401992 | Hospital Universitario Dr. Jose E. Gonzalez | Psoriasis (PsO)|Obesity & Overweight|Diabetes Mellitus - Type 2 | 2026-01-15 | PHASE4 |
| NCT05784402 | Novo Nordisk A+S | Healthy Participants | 2023-03-16 | PHASE1 |
| NCT03648281 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2018-08-24 | |
| NCT04153929 | Boehringer Ingelheim | Diabetes Mellitus, Type 2 | 2020-04-30 | PHASE2 |
| NCT06422624 | Bostal Drug Delivery Co., Ltd | Diabetes Mellitus, Type 2 | 2024-08 | PHASE1 |
| NCT05755360 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2023-02-21 | |
| NCT02827708 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2016-09-20 | PHASE3 |
| NCT05236517 | Novo Nordisk A+S | Obesity | 2022-02-08 | PHASE1 |
| NCT06659744 | Brigham and Women´s Hospital | Diabetes Mellitus, Type 2 | 2024-10-24 | |
| NCT04982575 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2021-08-02 | PHASE2 |
| NCT06639464 | Brigham and Women´s Hospital | Opioid Use Disorder | 2025-06-02 | PHASE2 |
| NCT03018028 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2017-01-10 | PHASE3 |
| NCT06788626 | Wei Hu|Chinese University of Hong Kong | Acute Ischemic Stroke|Large Vessel Occlusion|Neuroprotective Drugs|Endovascular Treatment | 2025-02 | PHASE3 |
| NCT03574584 | Novo Nordisk A+S | Metabolism and Nutrition Disorders|Overweight or Obesity | 2018-06-18 | PHASE1 |
| NCT03136484 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2017-03-15 | PHASE3 |
| NCT06716216 | BrightGene Bio-Medical Technology Co., Ltd.|BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. | Type 2 Diabetes Mellitus (T2DM) | 2024-11-29 | PHASE3 |
| NCT06045221 | Eli Lilly and Company | Type 2 Diabetes | 2023-09-22 | PHASE3 |
| NCT06534411 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2024-11-05 | PHASE3 |
| NCT07428746 | Emory University|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Diabetes Mellitus, Type 2 | 2026-04 | PHASE3 |
| NCT06118203 | Imperial College London | Pulmonary Embolism | 2022-01-02 | |
| NCT05630586 | Aarhus University Hospital|Bispebjerg Hospital|Glostrup University Hospital, Copenhagen|Odense University Hospital|Herning Hospital|Aalborg University Hospital|Rigshospitalet, Denmark | Acute Ischemic Stroke | 2023-04-12 | PHASE2 |
| NCT05537233 | Viral N. Shah|Juvenile Diabetes Research Foundation | Type 1 Diabetes|Obesity | 2023-04-11 | PHASE2 |
| NCT03596450 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2018-07-13 | PHASE4 |
| NCT07293325 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Adults With Simple Obesity | 2025-06-02 | NA |
| NCT06771115 | Zomagen Biosciences Ltd. | Obesity | 2025-01-07 | PHASE2 |
| NCT04938388 | Sansum Diabetes Research Institute|Novo Nordisk A+S | Diabetes Mellitus, Type 2|Glucose Metabolism Disorders (Including Diabetes Mellitus) | 2022-01-29 | PHASE4 |
| NCT07221214 | Vanderbilt University Medical Center|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Norton Healthcare|University of Louisville | HIV|Alcohol|Smoking Cigarette|Cardiovascular Disease Prevention | 2026-04-17 | PHASE2 |
| NCT05230615 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2022-04-01 | |
| NCT05144984 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2021-11-29 | PHASE2 |
| NCT07527195 | Novo Nordisk A+S | Obesity | 2026-04-10 | PHASE1 |
| NCT06716307 | Novo Nordisk A+S | Obesity | 2024-12-02 | PHASE1 |
| NCT03086330 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2017-03-15 | PHASE3 |
| NCT05938712 | University Health Network, Toronto | Kidney Transplant Recipients | 2023-10-24 | PHASE2 |
| NCT04537637 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2020-08-28 | |
| NCT03144271 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2|Healthy | 2007-06-11 | PHASE1 |
| NCT04524832 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2020-09-29 | PHASE1 |
| NCT06717698 | Novo Nordisk A+S | Chronic Kidney Disease | 2024-12-02 | PHASE2 |
| NCT05890976 | Novo Nordisk A+S | Overweight|Obesity | 2023-05-30 | PHASE3 |
| NCT05129891 | Novo Nordisk A+S | Healthy Volunteers|High Blood Cholesterol Levels|Type 2 Diabetes | 2021-11-03 | PHASE1 |
| NCT05788965 | University of Minnesota|Cystic Fibrosis Foundation | Cystic Fibrosis|Cystic Fibrosis-related Diabetes | 2023-10-16 | PHASE2|PHASE3 |
| NCT02254291 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2014-10-02 | PHASE3 |
| NCT06980623 | Brigham and Women´s Hospital | Type 2 Diabetes|Heart Failure | 2025-01-01 | |
| NCT02172313 | Novo Nordisk A+S | Diabetes|Healthy | 2014-06 | PHASE1 |
| NCT04083820 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2019-09-16 | |
| NCT05646706 | Novo Nordisk A+S | Obesity | 2023-01-04 | PHASE3 |
| NCT04174755 | University College Dublin|University of Copenhagen|Rush University Medical Center | Obesity|HIV-1-infection | 2022-06-22 | NA |
| NCT04892199 | Anders Fink-Jensen, MD, DMSci | Metabolic Disturbance|Schizophrenia|Type 2 Diabetes|Clozapine|GLP-1|Olanzapine | 2021-09-01 | PHASE4 |
| NCT07040592 | Yale University|National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcohol Use Disorder (AUD)|HIV | 2026-01-15 | PHASE2 |
| NCT05064735 | Novo Nordisk A+S | Obesity | 2021-10-01 | PHASE3 |
| NCT02146079 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2|Healthy | 2014-05-21 | PHASE1 |
| NCT05498610 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2022-08-11 | PHASE1 |
| NCT05616013 | Eli Lilly and Company|Versanis Bio, Inc. | Obesity|Obese|Overweight or Obesity | 2022-11-16 | PHASE2 |
| NCT05501483 | Karolinska Institutet|Karolinska University Hospital | Type 2 Diabetes | 2023-02-08 | NA |
| NCT07239570 | Peter Rossing|University Medical Center Groningen|Lund University|Instituto de Investigacion Sanitaria INCLIVA|Universit?tsklinikum Hamburg-Eppendorf | Chronic Kidney Disease(CKD) | 2025-06-20 | PHASE4 |
| NCT06449625 | Klaus Gottlob Müller|Novo Nordisk A+S|Independent Research Fund Denmark | Intestinal Mucositis|Inflammation|Chemotherapeutic Toxicity | 2024-08-12 | PHASE2 |
| NCT04466345 | University Health Network, Toronto | Major Depressive Disorder | 2021-10-06 | PHASE2 |
| NCT07389941 | University of Luebeck | Atrial Fibrillation (AF) | 2026-10 | PHASE4 |
| NCT06222437 | Methodist Health System | Polycystic Ovary Syndrome | 2026-02 | PHASE1 |
| NCT03914326 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2019-06-17 | PHASE3 |
| NCT07073053 | Taipei Veterans General Hospital, Taiwan | Glucagon-Like Peptide-1 Receptor Agonists|Type 2 Diabetes|Coronary Arterial Disease (CAD) | 2025-10-01 | PHASE4 |
| NCT02970942 | Novo Nordisk A+S | Hepatobiliary Disorders|Non-alcoholic Steatohepatitis | 2016-11-30 | PHASE2 |
| NCT05227196 | Novo Nordisk A+S | Healthy Volunteers|Type 2 Diabetes | 2022-02-04 | PHASE1 |
| NCT06797869 | Novo Nordisk A+S | Diabetes Mellitus, Type 2|Diabetic Peripheral Neuropathy | 2025-01-29 | PHASE2 |
| NCT05567796 | Novo Nordisk A+S | Obesity | 2022-11-01 | PHASE3 |
| NCT01572753 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2|Healthy | 2012-04-12 | PHASE1 |
| NCT05087342 | Loma Linda University|Novo Nordisk A+S | Obesity|Obesity; Drug|Overweight or Obesity|Weight Loss|Weight Loss Trajectory|Weight, Body | 2022-12-13 | PHASE3 |
| NCT00696657 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2008-06-03 | PHASE2 |
| NCT05746039 | University of Pennsylvania | Obesity|Interstitial Lung Disease|Chronic Obstructive Pulmonary Disease|Sarcoidosis, Pulmonary|Pulmonary Hypertension | 2024-01-29 | PHASE1|PHASE2 |
| NCT06057077 | Ministry of Health, Saudi Arabia | Type 1 Diabetes | 2024-01-01 | PHASE1|PHASE2 |
| NCT06154486 | Hospital Israelita Albert Einstein | Pneumonia, Aspiration|Anesthesia | 2023-06-19 | |
| NCT06318442 | Imperial College London | Steroid-Induced Diabetes|Steroid Induced Hyperglycemia | 2024-05-15 | NA |
| NCT02147431 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2014-05-21 | PHASE1 |
| NCT07056803 | University of Palermo | Diabetes Mellitus Type 2 | 2024-01-01 | |
| NCT05990374 | Nanjing First Hospital, Nanjing Medical University | Diabetes | 2023-08-01 | NA |
| NCT05424003 | Virginia Commonwealth University|Novo Nordisk A+S | NAFLD | 2024-02-22 | PHASE2 |
| NCT06323161 | Novo Nordisk A+S | Type 2 Diabetes | 2024-03-26 | PHASE3 |
| NCT03819153 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2019-06-17 | PHASE3 |
| NCT04862923 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2021-05-12 | |
| NCT04152915 | Novo Nordisk A+S | Healthy Volunteers|Diabetes Mellitus, Type 2 | 2019-11-25 | PHASE1 |
| NCT04601740 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2020-11-17 | |
| NCT07417618 | Brigham and Women´s Hospital | Type 2 Diabetes|Overweight|ASCVD | 2026-01-27 | |
| NCT06659679 | Brigham and Women´s Hospital | Diabetes Mellitus, Type 2 | 2024-10-24 | |
| NCT06015893 | National Institute on Drug Abuse (NIDA) | Addiction|Alcohol Use Disorder | 2023-10-17 | PHASE2 |
| NCT06387199 | McGill University Health Centre+Research Institute of the McGill University Health Centre | Type 1 Diabetes|Diabetes Mellitus | 2024-12-01 | PHASE2|PHASE3 |
| NCT07081178 | Novo Nordisk A+S | Obesity | 2025-08-08 | |
| NCT02557620 | Novo Nordisk A+S | Diabetes|Healthy | 2015-09 | PHASE1 |
| NCT07172867 | Halia Therapeutics, Inc. | Diabetes Mellitus, Type 2|Obesity | 2026-01-06 | PHASE2 |
| NCT05606471 | University of Nottingham|Medical Research Council | Type 2 Diabetes Mellitus in Obese | 2021-09-15 | PHASE4 |
| NCT07446998 | Veru Inc. | Obesity & Overweight|Mobility Disability|HOMA-IR | 2026-03-26 | PHASE2 |
| NCT05443334 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2022-07-28 | |
| NCT04615871 | Vladimír D?avík|Unity Health Toronto|Canadian Institutes of Health Research (CIHR)|University of Toronto | Covid19|Myocardial Injury | 2021-09-10 | PHASE2 |
| NCT03987919 | Eli Lilly and Company | Type 2 Diabetes | 2019-07-30 | PHASE3 |
| NCT06778967 | Gan & Lee Pharmaceuticals. | Type 2 Diabetes Mellitus (T2DM) | 2025-02-13 | PHASE3 |
| NCT04788511 | Novo Nordisk A+S | Obesity | 2021-03-16 | PHASE3 |
| NCT06613854 | University Medical Centre Ljubljana | Type 2 Diabetes Mellitus (T2DM) | 2024-10-01 | PHASE4 |
| NCT06500429 | Neurogastrx, Inc. | Overweight and Obesity|Healthy | 2024-06-24 | PHASE2 |
| NCT05520775 | University of North Carolina, Chapel Hill|National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcohol Use Disorder|Cigarette Smoking | 2022-09-02 | PHASE2 |
| NCT05569772 | Universitaire Ziekenhuizen KU Leuven|University Hospital, Antwerp|Universitair Ziekenhuis Brussel|General Hospital Groeninge|Onze Lieve Vrouw Hospital|Jessa Hospital|Ziekenhuis Netwerk Antwerpen (ZNA)|Vitaz|Centre Hospitalier Universitaire de Liege|Erasme University Hospital|Centre Hospitalier Mouscron|Jan Yperman Ziekenhuis|AZ Turnhout|AZ Sint-Lucas Brugge | Glucose Intolerance After a Recent History of Gestational Diabetes | 2023-09-14 | PHASE3 |
| NCT04251156 | Novo Nordisk A+S | Overweight|Obesity|Diabetes Mellitus, Type 2 | 2020-12-08 | PHASE3 |
| NCT05035082 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2021-09-01 | PHASE4 |
| NCT05078255 | Asger Lund, MD | Type 2 Diabetes|Obesity | 2022-01-27 | NA |
| NCT05877547 | Merck Sharp & Dohme LLC | Non-alcoholic Fatty Liver Disease|Fatty Liver, Nonalcoholic|NAFLD|Nonalcoholic Fatty Liver Disease|Nonalcoholic Steatohepatitis | 2023-06-23 | PHASE2 |
| NCT02212067 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2014-08-11 | PHASE1 |
| NCT06863363 | Shanghai Zhongshan Hospital | Non-diabetic Obesity | | PHASE4 |
| NCT01686945 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2|Healthy | 2012-09-19 | PHASE1 |
| NCT01923181 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2013-12-02 | PHASE2 |
| NCT07091500 | Washington University School of Medicine | Obesity|Skeletal Muscle | 2025-08-11 | NA |
| NCT03989232 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2019-06-19 | PHASE3 |
| NCT07564414 | Novo Nordisk A+S | Obesity|Type 2 Diabetes | 2026-05-21 | PHASE3 |
| NCT04109547 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2019-10-01 | PHASE3 |
| NCT05232708 | Novo Nordisk A+S | Healthy Volunteers (Diabetes Mellitus, Type 2) | 2022-01-19 | PHASE1 |
| NCT05564117 | Novo Nordisk A+S | Overweight|Obesity | 2022-10-11 | PHASE3 |
| NCT03611582 | Novo Nordisk A+S | Overweight|Obesity | 2018-08-01 | PHASE3 |
| NCT04126603 | Sabyasachi Sen | Diabetes Mellitus, Type 2 | 2019-08-01 | PHASE4 |
| NCT03015220 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2017-01-10 | PHASE3 |
| NCT04019197 | Case Western Reserve University|Medical University of South Carolina|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | HIV+AIDS|Lipohypertrophy|Obesity | 2019-05-16 | PHASE2 |
| NCT03659682 | Oslo University Hospital | Parkinson Disease | 2019-01-02 | PHASE2 |
| NCT06173778 | The University of Texas Health Science Center, Houston | Obesity|Overweight|Cigarette Smoking | 2024-04-23 | PHASE2 |
| NCT05473286 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2022-09-30 | |
| NCT03929679 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2019-05-28 | |
| NCT07184086 | Novo Nordisk A+S | Obesity | 2025-09-26 | PHASE1 |
| NCT03631186 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2018-09-12 | |
| NCT03357380 | Novo Nordisk A+S | Hepatobiliary Disorders|Non-alcoholic Fatty Liver Disease | 2017-11-28 | PHASE1 |
| NCT06475586 | University of Banja Luka | Psoriasis Vulgaris|Diabetes Type 2 | 2023-05-03 | PHASE4 |
| NCT06234111 | Hvidovre University Hospital | Obesity Morbid|Multimorbidity|Obesity | 2024-02-20 | |
| NCT03951753 | Eli Lilly and Company | Diabetes Mellitus, Type 2 | 2019-06-28 | PHASE1 |
| NCT06003153 | Massachusetts General Hospital|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Genetic Predisposition|Metabolic Diseases|Type 2 Diabetes | 2024-03-12 | PHASE4 |
| NCT05444153 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2022-10-06 | PHASE3 |
| NCT06423599 | Jens D Hove, MD,PHD | Heart Failure With Reduced Ejection Fraction|Obesity|Weight Loss|Chronic Heart Failure | 2024-05-17 | PHASE2|PHASE3 |
| NCT04451837 | Region Skane|G?teborg University | Type2 Diabetes | 2020-09-10 | PHASE2 |
| NCT02773381 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2016-06-02 | PHASE1 |
| NCT04624672 | Geisinger Clinic|Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2021-08-25 | PHASE4 |
| NCT05040971 | Novo Nordisk A+S | Obesity | 2021-09-06 | PHASE3 |
| NCT02845219 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2016-07 | PHASE1 |
| NCT02863328 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2016-08-10 | PHASE3 |
| NCT05394519 | Novo Nordisk A+S | Overweight|Obesity|Type 2 Diabetes Mellitus | 2023-02-01 | PHASE3 |
| NCT07465965 | Shanghai World Leader Pharmaceutical Co., Ltd. | Overweight|Obesity | 2026-03-02 | PHASE1 |
| NCT00813020 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2009-01 | PHASE1 |
| NCT07390110 | Brigham and Women´s Hospital | Type 2 Diabetes|Heart Failure | 2026-01-24 | |
| NCT03021187 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2017-02-02 | PHASE3 |
| NCT07411378 | Biophytis | Muscle Wasting|Obesity & Overweight|Obesity | 2026-07 | PHASE2 |
| NCT06184568 | Innovent Biologics (Suzhou) Co. Ltd. | Type 2 Diabetes|Obesity | 2024-02-29 | PHASE3 |
| NCT05716724 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2023-01-25 | |
| NCT06548490 | Milton S. Hershey Medical Center|New York University|University of Maryland|National Institute on Drug Abuse (NIDA) | Opioid Use Disorder|Opioid Abuse and Addiction|Narcotic-Related Disorders|Substance-Related Disorders|Chemically-Induced Disorders|Mental Disorder|Opioid | 2025-01-13 | PHASE2 |
| NCT05067621 | Yale University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type 2 Diabetes Mellitus|Impaired Glucose Tolerance|Non-Alcoholic Fatty Liver Disease|Obesity, Childhood | 2023-07-17 | PHASE2 |
| NCT03288740 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2017-09-21 | PHASE1 |
| NCT07282613 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2026-08-04 | PHASE3 |
| NCT03842202 | Novo Nordisk A+S | Overweight|Obesity | 2019-02-15 | PHASE1 |
| NCT05202353 | Boehringer Ingelheim | Obesity | 2024-10-01 | PHASE1 |
| NCT02849080 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | 2016-09-20 | PHASE3 |
| NCT02249871 | Novo Nordisk A+S | Diabetes|Healthy | 2014-09-24 | PHASE1 |
| NCT05390307 | Dasman Diabetes Institute | Type 1 Diabetes | 2023-04-01 | NA |
| NCT06060392 | Medanta, The Medicity, India | Liver Transplant; Complications|Diabete Mellitus | 2023-10-30 | NA |
| NCT06131372 | Novo Nordisk A+S | Chronic Kidney Disease|Type 2 Diabetes|Obesity | 2024-04-01 | PHASE2 |
| NCT04596631 | Novo Nordisk A+S | Diabetes Mellitus, Type 2 | 2020-11-02 | PHASE3 |
| NCT05649137 | Novo Nordisk A+S | Obesity|Diabetes Mellitus, Type 2 | 2023-01-04 | PHASE3 |
| NCT06042153 | University of Texas Southwestern Medical Center|University of North Carolina, Chapel Hill | Type 2 Diabetes|End Stage Renal Disease on Dialysis | 2023-12-05 | PHASE4 |
| NCT06827002 | University of Yaounde 1|J & A Oben Foundation | Obesity and Overweight|Appetite Regulation | 2023-02-12 | PHASE1|PHASE2 |
| NCT00833716 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2|Renal Impairment | 2009-02-02 | PHASE1 |
| NCT02210871 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2|Hepatic Impaired | 2014-08-07 | PHASE1 |
| NCT06779929 | Brigham and Women´s Hospital | Type 2 Diabetes | 2024-11-01 | |
| NCT05756764 | Louisiana State University Health Sciences Center in New Orleans|Tulane University|Pennington Biomedical Research Center|Ochsner Health System | Obesity | 2023-06-01 | |